Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results

OBJECTIVE: The 24‐week equivalent efficacy and comparable safety results of the biosimilar SB5 and reference adalimumab (ADA) from the phase III randomized study in patients with moderate‐to‐severe rheumatoid arthritis (RA) have been reported previously. We undertook this transition study to evaluat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Arthritis Rheumatol
Hlavní autoři: Weinblatt, Michael E., Baranauskaite, Asta, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz‐Rosiak, Krystyna, Baek, Inyoung, Ghil, Jeehoon
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Rheumatoid Arthritis
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6001519/
https://ncbi.nlm.nih.gov/pubmed/29439289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40444
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky